npj Parkinson's Disease (Dec 2021)

Predictors of clinically significant quality of life impairment in Parkinson’s disease

  • Santos García D.,
  • Teresa de Deus Fonticoba,
  • Carlos Cores,
  • Guillermo Muñoz,
  • Jose M. Paz González,
  • Cristina Martínez Miró,
  • Ester Suárez,
  • Silvia Jesús,
  • Miquel Aguilar,
  • Pau Pastor,
  • Lluis Planellas,
  • Marina Cosgaya,
  • Juan García Caldentey,
  • Nuria Caballol,
  • Inés Legarda,
  • Jorge Hernández Vara,
  • Iria Cabo,
  • Luis López Manzanares,
  • Isabel González Aramburu,
  • María A. Ávila Rivera,
  • Maria J. Catalán,
  • Víctor Nogueira,
  • Víctor Puente,
  • María Ruíz de Arcos,
  • Carmen Borrué,
  • Berta Solano Vila,
  • María Álvarez Sauco,
  • Lydia Vela,
  • Sonia Escalante,
  • Esther Cubo,
  • Francisco Carrillo Padilla,
  • Juan C. Martínez Castrillo,
  • Pilar Sánchez Alonso,
  • Maria G. Alonso Losada,
  • Nuria López Ariztegui,
  • Itziar Gastón,
  • Pedro Clavero,
  • Jaime Kulisevsky,
  • Marta Blázquez Estrada,
  • Manuel Seijo,
  • Javier Rúiz Martínez,
  • Caridad Valero,
  • Mónica Kurtis,
  • Oriol de Fábregues,
  • Jessica González Ardura,
  • Carlos Ordás,
  • Luis M. López Díaz,
  • Darrian McAfee,
  • Pablo Martinez-Martin,
  • Pablo Mir,
  • COPPADIS Study Group

DOI
https://doi.org/10.1038/s41531-021-00256-w
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Quality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson’s disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829–0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422–12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053–1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027–1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer–Lemeshow test, p = 0.665; R 2 = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663–17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975–22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients.